EGR1 Protein

Migration, Crosslink

📖

EGR1 Protein

active

wiki page Created: 2026-04-02T07:19:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-egr1-protein

📖 Wiki Page

protein1108 wordssynced 2026-04-02

EGR1 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">EGR1 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>EGR1 (Early Growth Response Protein 1)</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[EGR1](/genes/egr1)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[P18146](https://www.uniprot.org/uniprot/P18146)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~59.8 kDa</td>
</tr>
<tr>
<td class="label">Amino Acids</td>
<td>543</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Nucleus</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>C2H2-type zinc finger transcription factor</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (hippocampus, cortex, basal ganglia), peripheral nervous system</td>
</tr>
<tr>
<td class="label">Application</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">AD diagnosis</td>
<td>Blood/CSF</td>
</tr>
<tr>
<td class="label">PD progression</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">Treatment response</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">Disease severity</td>
<td>Peripheral blood mononuclear cells</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">HDAC inhibitors</td>
<td>Increase EGR1 expression</td>
</tr>
<tr>
<td class="label">TrkB agonists</td>

...

EGR1 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">EGR1 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>EGR1 (Early Growth Response Protein 1)</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[EGR1](/genes/egr1)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[P18146](https://www.uniprot.org/uniprot/P18146)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~59.8 kDa</td>
</tr>
<tr>
<td class="label">Amino Acids</td>
<td>543</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Nucleus</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>C2H2-type zinc finger transcription factor</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (hippocampus, cortex, basal ganglia), peripheral nervous system</td>
</tr>
<tr>
<td class="label">Application</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">AD diagnosis</td>
<td>Blood/CSF</td>
</tr>
<tr>
<td class="label">PD progression</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">Treatment response</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">Disease severity</td>
<td>Peripheral blood mononuclear cells</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">HDAC inhibitors</td>
<td>Increase EGR1 expression</td>
</tr>
<tr>
<td class="label">TrkB agonists</td>
<td>Indirect EGR1 activation</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-EGR1 delivery</td>
</tr>
<tr>
<td class="label">Epigenetic</td>
<td>DNA demethylation</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/arm" style="color:#ef9a9a">ARM</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">187 edges</a></td>
</tr>
</table>

EGR1 (Early Growth Response Protein 1), encoded by the [EGR1](/genes/egr1) gene on chromosome 5q31, is a C2H2-type zinc finger transcription factor that functions as a master regulator of immediate-early gene programs in the brain. It is rapidly induced by neuronal activity, calcium influx, growth factors, oxidative stress, and inflammatory signals[@odonovan2018]. EGR1 regulates genes critical for synaptic plasticity, memory consolidation, neurotrophin signaling, and neuronal survival. Dysregulation of EGR1 is increasingly recognized as a feature of both Alzheimer's disease (AD) and Parkinson's disease (PD)[@li2019][@kim2018].

Protein Information

Structure

Domain Architecture

EGR1 contains several functionally distinct regions[@uniprot_egr1]:

N-terminal repression domain (1-200 aa): Interacts with co-repressors including N-CoR and SMRT
Central activation domain (200-330 aa): Recruits transcriptional co-activators
C2H2 Zinc Finger Domain (330-420 aa): Three C2H2-type zinc fingers that mediate sequence-specific DNA binding
C-terminal region (420-543 aa): Regulatory post-translational modification sites

DNA Binding

The C2H2 zinc finger domain binds the consensus sequence GCG(T/G)GGGCG (EGR1 binding site, EBS) found in promoter/enhancer regions of target genes. Each zinc finger coordinates a zinc ion through conserved cysteine and histidine residues, creating a beta-beta-alpha fold that contacts the DNA major groove.

Normal Function

Immediate-Early Gene Response

EGR1 is one of the most rapidly induced transcription factors in response to neuronal stimulation[@odonovan2018]:

Synaptic activity triggers calcium influx through NMDA receptors and voltage-gated calcium channels

CaMKII and MAPK/ERK pathways are activated

EGR1 transcription peaks 30-60 minutes post-stimulation

EGR1 protein translocates to the nucleus and activates target gene expression

Transcriptional Targets

EGR1 activates a wide array of neuroprotective and plasticity-related genes:

Neurotrophic factors: [BDNF](/proteins/bdnf-protein), [NGF](/proteins/ngf-protein), GDNF
Synaptic proteins: Synapsin I/II, PSD-95 (DLG4), CaMKII
Anti-apoptotic proteins: Bcl-2, Bcl-xL, Mcl-1
Antioxidant genes: SOD1, catalase, thioredoxin
Immediate-early genes: c-Fos (FOS), Arc (ARC), Nras

Neuroprotective Signaling

EGR1 provides neuroprotection through multiple mechanisms[@cao2020]:

BDNF induction: EGR1 directly activates BDNF transcription, promoting synaptic plasticity and neuronal survival

Anti-apoptotic gene expression: Bcl-2 family proteins inhibit mitochondrial apoptosis

Antioxidant response: Nqo1, Hmox1, and other phase II detoxification genes

Synaptic protein regulation: Maintains synaptic structure and function

Role in Alzheimer's Disease

EGR1 Dysregulation in AD

In Alzheimer's disease, EGR1 expression is consistently altered[@kim2018][@li2019]:

Downregulation in affected brain regions: Reduced EGR1 mRNA and protein in AD hippocampus and cortex
Correlation with NFT burden: Lower EGR1 levels correlate with higher Braak stage and NFT density
Relationship to amyloid pathology: Aβ42 exposure reduces EGR1 expression in neuronal cultures
Synaptic dysfunction: Loss of EGR1 may contribute to memory impairment through reduced neurotrophic support

Mechanisms of EGR1 Loss in AD

Several mechanisms contribute to EGR1 dysregulation in AD:

Aβ toxicity: Direct suppression of EGR1 transcription by Aβ oligomers via histone modifications

Tau pathology: Hyperphosphorylated tau interferes with synaptic activity-dependent EGR1 induction

Epigenetic silencing: Increased DNA methylation at the EGR1 promoter in AD brain[@li2019]

Calcium dysregulation: Impaired calcium signaling reduces CaMKII-dependent EGR1 activation

Therapeutic Implications

EGR1-enhancing strategies are being explored for AD[@gao2022]:

HDAC inhibitors: Trichostatin A and SAHA increase EGR1 expression in AD models
BDNF mimetics: Small molecules that activate TrkB signaling and indirectly enhance EGR1
Epigenetic modulators: Demethylating agents that restore EGR1 promoter activity
Cell-based therapy: iPSC-derived neurons with enhanced EGR1 expression

Role in Parkinson's Disease

EGR1 in Dopaminergic Neurons

EGR1 plays important roles in dopaminergic neuron survival and function[@wang2021]:

Neuroprotective effects: EGR1 overexpression protects MN9D cells against 6-OHDA and MPTP toxicity
Regulation of TH: EGR1 can regulate tyrosine hydroxylase (TH) expression
Synaptic maintenance: EGR1 supports synaptic connectivity in dopaminergic circuits
Response to injury: EGR1 is rapidly induced in response to dopaminergic neurotoxins

EGR1 in PD Models

MPTP model: EGR1 is transiently induced in substantia nigra after MPTP treatment
6-OHDA model: EGR1 induction correlates with neuroprotective responses
Alpha-synuclein models: Aggregation pathology may suppress EGR1 activity
LRRK2 models: Pathogenic LRRK2 mutations affect EGR1 regulatory pathways

Therapeutic Targeting in PD

AAV-EGR1: Gene therapy vectors for delivering EGR1 to nigral neurons
EGR1 inducers: Small molecules that activate EGR1 transcription (e.g., nobiletin)
Combination approaches: EGR1 enhancement combined with GDNF or BDNF therapy

Animal Models

EGR1 Knockout Mice

Lethal phenotype: Egr1 null mice die postnatally with incomplete cardiac development
Neuronal-specific knockout: Shows impaired synaptic plasticity, spatial memory deficits
Behavioral deficits: Reduced LTP in hippocampus, poor contextual fear conditioning

Conditional Overexpression Models

Neuronal EGR1 overexpression: Rescues cognitive deficits in AD mouse models
Synaptic protection: EGR1 overexpression protects against excitotoxicity and oxidative stress
Memory enhancement: Enhanced object recognition and spatial memory

Biomarkers and Diagnostics

EGR1 as a Biomarker

Therapeutic Pipeline

Cross-Links

[EGR1 Gene](/genes/egr1)
[BDNF Protein](/proteins/bdnf-protein)
[Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Transcription Factor Pathways](/mechanisms/transcription-factor-pathways)

References

[Li Y, Yu H, Wang J, et al., EGR1 and tau pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[O'Donovan KJ, Makoveichuk A, Miao J, et al., EGR1 function in synaptic plasticity and memory consolidation (2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)

[Kim HJ, Park SY, Lee JY, et al., EGR1 is downregulated in Alzheimer's disease brain (2018)](https://pubmed.ncbi.nlm.nih.gov/30583742/)

[Cao A, Wu Z, Li X, et al., EGR1 regulates hippocampal synaptic plasticity via BDNF/TrkB (2020)](https://pubmed.ncbi.nlm.nih.gov/32048123/)

[Wang J, Fang Q, Liu Z, et al., EGR1 as therapeutic target for Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33989567/)

[Gao L, Chen X, Zhang Q, et al., EGR1-mediated neuroprotection against beta-amyloid toxicity (2022)](https://doi.org/10.1007/s10571-021-01138-8)

📖 View canonical wiki page →

Related Entities

EGR1PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-egr1-protein
kg_node_id	EGR1PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-dd512e582185
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-egr1-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

20

Outgoing

26

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

EGR1 Protein

EGR1 Protein

Overview

EGR1 Protein

Overview

Protein Information

Structure

Domain Architecture

DNA Binding

Normal Function

Immediate-Early Gene Response

Transcriptional Targets

Neuroprotective Signaling

Role in Alzheimer's Disease

EGR1 Dysregulation in AD

Mechanisms of EGR1 Loss in AD

Therapeutic Implications

Role in Parkinson's Disease

EGR1 in Dopaminergic Neurons

EGR1 in PD Models

Therapeutic Targeting in PD

Animal Models

EGR1 Knockout Mice

Conditional Overexpression Models

Biomarkers and Diagnostics

EGR1 as a Biomarker

Therapeutic Pipeline

Cross-Links

See Also

References

cites (1)

derives from (12)

supports (10)

💬 Discussion